sorafenib has been researched along with fangchinoline in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (fangchinoline) | Trials (fangchinoline) | Recent Studies (post-2010) (fangchinoline) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 107 | 0 | 61 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, YT; Feng, Y; Feng, Z; Huang, L; Lan, J; Liu, Y; Lu, Y; Pan, W; Wang, N | 1 |
1 other study(ies) available for sorafenib and fangchinoline
| Article | Year |
|---|---|
Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.
Topics: Acetylation; Animals; Carcinoma, Hepatocellular; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Mice; Sorafenib; Thioredoxins; Vorinostat | 2023 |